Efficacy and safety of a 72‐h infusion of prostacyclin (1 ng/kg/min) in mechanically ventilated patients with pulmonary infection and endotheliopathy—protocol for the multicenter randomized, placebo‐controlled, blinded, investigator‐initiated <scp>CO
This trial will investigate the efficacy and safety of prostacyclin vs. placebo for 72-hours in mechanically ventilated patients with any suspected pulmonary infection and severe endotheliopathy, as defined by sTM ≥4 ng/mL. Trial endpoints focus on the potential effect of prostacyclin to reduce 28-day all-cause mortality.
Authors
- Pär I. Johansson (ORCID: https://orcid.org/0000-0001-9778-5964)
- Lars Peter Kloster Andersen (ORCID: https://orcid.org/0000-0003-0053-2560)
- Jakob Stensballe (ORCID: https://orcid.org/0000-0002-2351-9273)
- Niels Clausen (ORCID: https://orcid.org/0000-0002-4370-859X)
- Morten H. Bestle (ORCID: https://orcid.org/0000-0001-6585-2659)
- Theis Lange (ORCID: https://orcid.org/0000-0001-6807-8347)
- Peter Søe‐Jensen
Institutions
- University of Copenhagen (DK)
- Frederiksberg Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Zealand University Hospital (DK)
- Zealand University Hospital Køge (DK)
Publication Details
- Journal
- Acta Anaesthesiologica Scandinavica
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1111/aas.14565
- Citations
- 1
- Primary Topic
- Respiratory Support and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Novo Nordisk
- Alfred Benzon Foundation
- Novo Nordisk Fonden